Geron (GERN) Rating Increased to Hold at ValuEngine

ValuEngine upgraded shares of Geron (NASDAQ:GERN) from a sell rating to a hold rating in a report issued on Wednesday, March 14th.

Other analysts also recently issued reports about the stock. BidaskClub raised shares of Geron from a hold rating to a buy rating in a research note on Friday, March 9th. Zacks Investment Research downgraded shares of Geron from a buy rating to a hold rating in a research note on Tuesday, January 2nd. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of Hold and an average price target of $4.50.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ GERN traded down $0.16 during mid-day trading on Wednesday, reaching $3.48. 5,365,790 shares of the company were exchanged, compared to its average volume of 14,195,062. Geron has a 52 week low of $1.74 and a 52 week high of $6.68. The company has a market capitalization of $584.78, a P/E ratio of -19.33 and a beta of 2.29.

Geron (NASDAQ:GERN) last posted its quarterly earnings data on Friday, March 16th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). The company had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.41 million. Geron had a negative return on equity of 25.25% and a negative net margin of 2,621.22%. The business’s revenue was up 103.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.05) earnings per share. sell-side analysts predict that Geron will post 0.01 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in GERN. State Street Corp grew its holdings in Geron by 9.8% in the second quarter. State Street Corp now owns 5,127,578 shares of the biopharmaceutical company’s stock worth $14,205,000 after purchasing an additional 459,700 shares during the period. Russell Investments Group Ltd. grew its holdings in Geron by 783.9% in the third quarter. Russell Investments Group Ltd. now owns 363,990 shares of the biopharmaceutical company’s stock worth $794,000 after purchasing an additional 322,810 shares during the period. Vanguard Group Inc. grew its holdings in Geron by 4.1% in the second quarter. Vanguard Group Inc. now owns 7,406,968 shares of the biopharmaceutical company’s stock worth $20,518,000 after purchasing an additional 294,785 shares during the period. Deutsche Bank AG lifted its stake in shares of Geron by 70.1% in the fourth quarter. Deutsche Bank AG now owns 696,410 shares of the biopharmaceutical company’s stock worth $1,251,000 after buying an additional 286,979 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. bought a new position in shares of Geron in the fourth quarter worth approximately $481,000. Institutional investors and hedge funds own 36.89% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Geron (GERN) Rating Increased to Hold at ValuEngine” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/07/valuengine-upgrades-geron-gern-to-hold.html.

Geron Company Profile

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply